CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ozon Farmatsevtika PAO is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ozon Farmatsevtika PAO
Iubileinaia, 2b, =
Phone: +7 8486229000p:+7 8486229000 ZHIGULEVSK, 445034  Russian Federation
Business Summary
Ozon Farmatsevtika PAO, formerly Ozon Farmatsevtika AO, is a Russia-based pharmaceutical company operating in all pharmaceutical niches-from traditional small-molecule drugs to toxic oncology medications and complex, science-intensive biotechnological drugs. The Company operates across segments, such as traditional small-molecule drugs, high-toxicity and oncology medications, complex biotechnological products. The Company's divisions include Ozon and Ozon Pharm (specializing in the production of finished dosage forms using synthetic active pharmaceutical ingredients (APIs)); Ozon Medica (focused on the development and production of oncology drugs and therapies for severe systemic autoimmune diseases); Mabscale (providing full-cycle development and manufacturing of biopharmaceuticals based on monoclonal antibodies and other recombinant proteins).
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

General Information
Number of Employees: 3,005 (As of 12/31/2024)
Outstanding Shares: 1,085,644,000 (As of 12/31/2024)


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, February 1, 2026